YES1是小细胞肺癌中可成药的致癌靶点
该研究在小细胞肺癌临床样本中评估YES1水平与预后的关联,并通过体外和体内实验进行遗传与药理抑制验证。结果显示YES1过表达或增益/扩增分别见于31%和26%的病例,为独立不良预后预测因子;抑制YES1可减少增殖、器官样体形成、肿瘤生长和转移,并增加放射敏感性。
要点
- YES1过表达或增益/扩增分别见于31%和26%的小细胞肺癌病例,为独立不良预后预测因子。
- 遗传敲低YES1显著减少细胞增殖、三维器官样体形成、肿瘤生长和远处转移,并导致广泛凋亡和肿瘤消退。
- YES1抑制剂CH6953755或达沙替尼在器官样体和细胞/患者来源异种移植中诱导明显抗肿瘤活性。
核心结论
- YES1是小细胞肺癌新的可成药致癌靶点和生物标志物,有望推进部分小细胞肺癌患者的临床管理。
研究设计与样本
- 研究评估小细胞肺癌临床样本中YES1水平与预后的关联。
- 体外进行增殖、凋亡、细胞周期和细胞毒性功能实验。
- 体内在细胞来源和患者来源异种移植及转移模型中评估YES1的遗传和药理抑制。
- 检测小鼠和患者血浆来源外泌体中的YES1水平。
主要发现
- YES1过表达见于31%的病例,YES1增益/扩增见于26%的病例,跨分子亚组。
- YES1为独立不良预后预测因子。
- 遗传敲低YES1显著减少细胞增殖、三维器官样体形成、肿瘤生长和远处转移,导致广泛凋亡和肿瘤消退。
- YES1抑制的细胞显示复制体和DNA修复过程改变,对 irradiation 敏感。
- YES1抑制剂CH6953755或达沙替尼在器官样模型及细胞来源和患者来源异种移植中诱导明显抗肿瘤活性。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: SCLC is an extremely aggressive subtype of lung cancer without approved targeted therapies. Here we identified YES1 as a novel targetable oncogene driving SCLC maintenance and metastasis. METHODS: Association between YES1 levels and prognosis was evaluated in SCLC clinical samples. In vitro functional experiments for proliferation, apoptosis, cell cycle, and cytotoxicity were performed. Genetic and pharmacologic inhibition of YES1 was evaluated in vivo in cell- and patient-derived xenografts and metastasis. YES1 levels were evaluated in mouse and patient plasma-derived exosomes. RESULTS: Overexpression or gain/amplification of YES1 was identified in 31% and 26% of cases, respectively, across molecular subgroups, and was found as an independent predictor of poor prognosis. Genetic depletion of YES1 dramatically reduced cell proliferation, three-dimensional organoid formation, tumor growth, and distant metastasis, leading to extensive apoptosis and tumor regressions. Mechanistically, YES1-inhibited cells revealed alterations in the replisome and DNA repair processes, that conferred sensitivity to irradiation. Pharmacologic blockade with the novel YES1 inhibitor CH6953755 or dasatinib induced marked antitumor activity in organoid models and cell- and patient-derived xenografts. YES1 protein was detected in plasma exosomes from patients and mouse models, with levels matching those of tumors, suggesting that circulating YES1 could represent a biomarker for patient selection/monitoring. CONCLUSIONS: Our results provide evidence that YES1 is a new druggable oncogenic target and biomarker to advance the clinical management of a subpopulation of patients with SCLC.
引用
- Redin E, Garrido-Martin EM, Valencia K, et al. YES1 Is a Druggable Oncogenic Target in SCLC. J Thorac Oncol. 2022. PMID: 35988891. doi:10.1016/j.jtho.2022.08.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。